Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility

Infection and Immunity

Volumn 78, Issue 10, 2010, Pages 4402-4420

  Bishop, Anne L ^a   Schild, Stefan ^b   Patimalla, Bharathi ^a   Klein, Brian ^a   Camilli, Andrew ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; LIPOPOLYSACCHARIDE; OUTER MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CHOLERA; CONTROLLED STUDY; EPIDEMIC; FEMALE; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; VIBRIO CHOLERAE;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CELL MEMBRANE; CHOLERA; CHOLERA VACCINES; FEMALE; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULINS; MICE; MILK; SECRETORY VESICLES; VIBRIO CHOLERAE;

EID: 77957741128     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00398-10     Document Type: Article

References (85)

1. Ahmed, T., A. M. Svennerholm, A. Al Tarique, G. N. Sultana, and F. Qadri. 2009. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine 27:1433-1439.
2. Alaniz, R. C., B. L. Deatherage, J. C. Lara, and B. T. Cookson. 2007. Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo. J. Immunol. 179:7692-7701.
3. Albert, M. J., K. Alam, M. Ansaruzzaman, F. Qadri, and R. B. Sack. 1994. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR. J. Infect. Dis. 169:230-231.
4. Albert, M. J., K. Alam, A. S. Rahman, S. Huda, and R. B. Sack. 1994. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J. Infect. Dis. 169:709-710.
5. Albert, M. J., A. K. Siddique, M. S. Islam, A. S. Faruque, M. Ansaruzzaman, S. M. Faruque, and R. B. Sack. 1993. Large outbreak of clinical cholera due to Vibrio cholerae non-O1 in Bangladesh. Lancet 341:704.
6. Ali, M., M. Emch, L. Von Seidlein, M. Yunus, D. A. Sack, M. Rao, J. Holmgren, and J. Clemens. 2005. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366:44-49.
7. Angelichio, M. J., J. Spector, M. K. Waldor, and A. Camilli. 1999. Vibrio cholerae intestinal population dynamics in the suckling mouse model of infection. Infect. Immun. 67:3733-3739.
8. Anh, D. D., D. G. Canh, A. Lopez, V. D. Thiem, P. T. Long, N. H. Son, J. Deen, L. Von Seidlein, R. Carbis, S. Han, S. Shin, S. Attridge, J. Holmgren, and J. Clemens. 2007. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25:1149-1155.
9. Attridge, S. R., and J. Holmgren. 2009. Vibrio cholerae O139 capsular polysaccharide confers complement resistance in the absence or presence of antibody yet presents a productive target for cell lysis: implications for detection of bactericidal antibodies. Microb. Pathog. 47:314-320.
10. Attridge, S. R., C. Johansson, D. D. Trach, F. Qadri, and A. M. Svennerholm. 2002. Sensitive microplate assay for detection of bactericidal antibodies to Vibrio cholerae O139. Clin. Diagn. Lab. Immunol. 9:383-387.
11. Attridge, S. R., G. Wallerstrom, B. L. Li, R. Morona, and J. Holmgren. 2009. Differential immunogenicity of Vibrio cholerae O139 variants expressing different combinations of naturally occurring and atypical forms of the serogroup polysaccharide. Vaccine 27:1055-1061.
12. Belshe, R. B., K. L. Nichol, S. B. Black, H. Shinefield, J. Cordova, R. Walker, C. Hessel, I. Cho, and P. M. Mendelman. 2004. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin. Infect. Dis. 39:920-927.
13. Benenson, A. S., A. Saad, and W. H. Mosley. 1968. Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull. World Health Organ. 38:277-285.
14. Beveridge, T. J. 1999. Structures of gram-negative cell walls and their derived membrane vesicles. J. Bacteriol. 181:4725-4733.
15. Black, R. E., M. M. Levine, M. L. Clements, C. R. Young, A. M. Svennerholm, and J. Holmgren. 1987. Protective efficacy in humans of killed wholevibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect. Immun. 55:1116-1120.
16. Bramwell, V. W., and Y. Perrie. 2006. Particulate delivery systems for vaccines: what can we expect? J. Pharm. Pharmacol. 58:717-728.
17. Butler, S. M., and A. Camilli. 2005. Going against the grain: chemotaxis and infection in Vibrio cholerae. Nat. Rev. Microbiol. 3:611-620.
18. Camilli, A., S. Schild, and E. J. Nelson. 16 April 2009. Cholera Vaccines. International patent WO/2009/049013.
19. Chandrasekhar, U., S. Sinha, H. R. Bhagat, V. B. Sinha, and B. S. Srivastava. 1994. Comparative efficacy of biodegradable liposomes and microspheres as carriers for delivery of Vibrio cholerae antigens in the intestine. Vaccine 12:1384-1388.
20. Chatterjee, S. N., and K. Chaudhuri. 2003. Lipopolysaccharides of Vibrio cholerae. I. Physical and chemical characterization. Biochim. Biophys. Acta 1639:65-79.
21. Chatterjee, S. N., and J. Das. 1967. Electron microscopic observations on the excretion of cell-wall material by Vibrio cholerae. J. Gen. Microbiol. 49:1-11.
22. Chen, D. J., N. Osterrieder, S. M. Metzger, E. Buckles, A. M. Doody, M. P. DeLisa, and D. Putnam. 2010. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc. Natl. Acad. Sci. U. S. A. 107:3099-3104.
23. Cholera Working Group, I. C. D. D. R., Bangladesh. 1993. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Lancet 342:387-390.
24. Clemens, J. 1990. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335:270-273.
25. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, P. K. Neogy, B. Stanton, N. Huda, M. U. Khan, B. A. Kay, M. R. Khan, et al. 1988. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. 158:372-377.
26. Comstock, L. E., D. Maneval, P. Panigrahi, A. Joseph, M. M. Levine, J. B. Kaper, J. G. Morris, and J. A. Johnson. 1995. The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect. Immun. 63:317-323.
27. Cumberland, S. 2009. An old enemy returns. Bull. World Health Organ. 87:85-86.
28. Donnenberg, M. S., and J. B. Kaper. 1991. Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect. Immun. 59:4310-4317.
29. Eko, F. O., T. Schukovskaya, E. Y. Lotzmanova, V. V. Firstova, N. V. Emalyanova, S. N. Klueva, A. L. Kravtzov, L. F. Livanova, V. V. Kutyrev, J. U. Igietseme, and W. Lubitz. 2003. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 21:3663-3674.
30. Eubanks, E. R., M. N. Guentzel, and L. J. Berry. 1977. Evaluation of surface components of Vibrio cholerae as protective immunogens. Infect. Immun. 15:533-538.
31. Fiocca, R., V. Necchi, P. Sommi, V. Ricci, J. Telford, T. L. Cover, and E. Solcia. 1999. Release of Helicobacter pylori vacuolating cytotoxin by both a specific secretion pathway and budding of outer membrane vesicles. Uptake of released toxin and vesicles by gastric epithelium. J. Pathol. 188:220-226.
32. Gallucci, S., and P. Matzinger. 2001. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13:114-119.
33. Goldman, A. S. 2007. The immune system in human milk and the developing infant. Breastfeed. Med. 2:195-204.
34. Guentzel, M. N., L. H. Field, E. R. Eubanks, and L. J. Berry. 1977. Use of fluorescent antibody in studies of immunity to cholera in infant mice. Infect. Immun. 15:539-548.
35. Haneberg, B., and J. Holst. 2002. Can nonliving nasal vaccines be made to work? Expert Rev. Vaccines 1:227-232.
36. Harris, J., R. Larocque, F. Chowdhury, A. Khan, T. Logvinenko, A. Faruque, E. Ryan, F. Qadri, S. Calderwood, and A. Ko. 2008. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl. Trop. Dis. 2:e221.
37. Hisatsune, K., S. Kondo, Y. Isshiki, T. Iguchi, and Y. Haishima. 1993. Occurrence of 2-O-methyl-N-(3-deoxy-L-glycero-tetronyl)-D-perosamine (4-amino-4,6-dideoxy-D-manno-pyranose) in lipopolysaccharide from Ogawa but not from Inaba O forms of O1 Vibrio cholerae. Biochem. Biophys. Res. Commun. 190:302-307.
38. Hisatsune, K., S. Kondo, Y. Isshiki, T. Iguchi, Y. Kawamata, and T. Shimada. 1993. O-antigenic lipopolysaccharide of Vibrio cholerae O139 Bengal, a new epidemic strain for recent cholera in the Indian subcontinent. Biochem. Biophys. Res. Commun. 196:1309-1315.
39. Hitchcock, P. J., and T. M. Brown. 1983. Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J. Bacteriol. 154:269-277.
40. Horstman, A. L., and M. J. Kuehn. 2000. Enterotoxigenic Escherichia coli secretes active heat-labile enterotoxin via outer membrane vesicles. J. Biol. Chem. 275:12489-12496.
41. Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68.
42. Iwanaga, M., K. Yamamoto, N. Higa, Y. Ichinose, N. Nakasone, and M. Tanabe. 1986. Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 El Tor. Microbiol. Immunol. 30:1075-1083.
43. Johnson, J. A., C. A. Salles, P. Panigrahi, M. J. Albert, A. C. Wright, R. J. Johnson, and J. G. Morris. 1994. Vibrio cholerae O139 synonym bengal is closely related to Vibrio cholerae El Tor but has important differences. Infect. Immun. 62:2108-2110.
44. Kadurugamuwa, J. L., and T. J. Beveridge. 1998. Delivery of the nonmembrane-permeative antibiotic gentamicin into mammalian cells by using Shigella flexneri membrane vesicles. Antimicrob. Agents Chemother. 42:1476-1483.
45. Keenan, J. I., S. G. Rijpkema, Z. Durrani, and J. A. Roake. 2003. Differences in immunogenicity and protection in mice and guinea pigs following intranasal immunization with Helicobacter pylori outer membrane antigens. FEMS Immunol. Med. Microbiol. 36:199-205.
46. Lee, S. H., S. M. Butler, and A. Camilli. 2001. Selection for in vivo regulators of bacterial virulence. Proc. Natl. Acad. Sci. U. S. A. 98:6889-6894.
47. Levine, M. M., R. E. Black, M. L. Clements, L. Cisneros, D. R. Nalin, and C. R. Young. 1981. Duration of infection-derived immunity to cholera. J. Infect. Dis. 143:818-820.
48. Levine, M. M., J. B. Kaper, D. Herrington, G. Losonsky, J. G. Morris, M. L. Clements, R. E. Black, B. Tall, and R. Hall. 1988. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect. Immun. 56:161-167.
49. Longini, I. M., M. Yunus, K. Zaman, A. K. Siddique, R. B. Sack, and A. Nizam. 2002. Epidemic and endemic cholera trends over a 33-year period in Bangladesh. J. Infect. Dis. 186:246-251.
50. Lopez, A., J. Clemens, J. Deen, and L. Jodar. 2008. Cholera vaccines for the developing world. Hum. Vaccin. 4:165-169.
51. Mann, J. F., R. Acevedo, J. D. Campo, O. Perez, and V. A. Ferro. 2009. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Rev. Vaccines 8:103-112.
52. Miller, V. L., V. J. DiRita, and J. J. Mekalanos. 1989. Identification of toxS, a regulatory gene whose product enhances toxR-mediated activation of the cholera toxin promoter. J. Bacteriol. 171:1288-1293.
53. Miller, V. L., and J. J. Mekalanos. 1988. A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J. Bacteriol. 170:2575-2583.
54. Moisi, M., C. Jenul, S. M. Butler, A. New, S. Tutz, J. Reidl, K. E. Klose, A. Camilli, and S. Schild. 2009. A novel regulatory protein involved in motility of Vibrio cholerae. J. Bacteriol. 191:7027-7038.
55. Mosley, W. H., S. Ahmad, A. S. Benenson, and A. Ahmed. 1968. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull. World Health Organ. 38:777-785.
56. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350:896.
57. Nelson, E., A. Chowdhury, J. Flynn, S. Schild, L. Bourassa, Y. Shao, R. Larocque, S. B. Calderwood, F. Qadri, and A. Camilli. 2008. Transmission of Vibrio cholerae is antagonized by lytic phage and entry into the aquatic environment. PLoS Pathog. 4:e1000187.
58. Nesper, J., A. Kraiss, S. Schild, J. Blass, K. E. Klose, J. Bockemühl, and J. Reidl. 2002. Comparative and genetic analyses of the putative Vibrio cholerae lipopolysaccharide core oligosaccharide biosynthesis (wav) gene cluster. Infect. Immun. 70:2419-2433.
59. Nesper, J., S. Schild, C. M. Lauriano, A. Kraiss, K. E. Klose, and J. Reidl. 2002. Role of Vibrio cholerae O139 surface polysaccharides in intestinal colonization. Infect. Immun. 70:5990-5996.
60. Nygren, E., J. Holmgren, and S. R. Attridge. 2008. Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae. Vaccine 26:6784-6790.
61. Ogundele, M. 2001. Role and significance of the complement system in mucosal immunity: particular reference to the human breast milk complement. Immunol. Cell Biol. 79:1-10.
62. Qadri, F., M. I. Chowdhury, S. M. Faruque, M. A. Salam, T. Ahmed, Y. A. Begum, A. Saha, A. Al Tarique, L. V. Seidlein, E. Park, K. P. Killeen, J. Mekalanos, J. D. Clemens, D. A. Sack, and PXV Study Group. 2007. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 25:231-238.
63. Qadri, F., G. Mohi, J. Hossain, T. Azim, A. M. Khan, M. A. Salam, R. B. Sack, M. J. Albert, and A. M. Svennerholm. 1995. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin. Diagn. Lab. Immunol. 2:685-688.
64. Ramamurthy, T., S. Garg, R. Sharma, S. K. Bhattacharya, G. B. Nair, T. Shimada, T. Takeda, T. Karasawa, H. Kurazano, A. Pal, et al. 1993. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet 341:703-704.
65. Roberts, R., G. Moreno, D. Bottero, M. E. Gaillard, M. Fingermann, A. Graieb, M. Rumbo, and D. Hozbor. 2008. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine 26:4639-4646.
66. Ryan, E., S. B. Calderwood, and F. Qadri. 2006. Live attenuated oral cholera vaccines. Expert Rev. Vaccines 5:483-494.
67. Sack, D. A., R. B. Sack, and C. L. Chaignat. 2006. Getting serious about cholera. N. Engl. J. Med. 355:649-651.
68. Saha, D., R. Larocque, A. Khan, J. Harris, Y. A. Begum, S. M. Akramuzzaman, A. S. Faruque, E. Ryan, F. Qadri, and S. B. Calderwood. 2004. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J. Infect. Dis. 189:2318-2322.
69. Sánchez, J., and J. Holmgren. 2008. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell. Mol. Life Sci. 65: 1347-1360.
70. Schild, S., E. J. Nelson, A. L. Bishop, and A. Camilli. 2009. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect. Immun. 77:472-484.
71. Schild, S., E. J. Nelson, and A. Camilli. 2008. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect. Immun. 76:4554-4563.
72. Song, T., F. Mika, B. Lindmark, Z. Liu, S. Schild, A. Bishop, J. Zhu, A. Camilli, J. Johansson, J. Vogel, and S. N. Wai. 2008. A new Vibrio cholerae sRNA modulates colonization and affects release of outer membrane vesicles. Mol. Microbiol. 70:100-111.
73. Stroeher, U. H., L. E. Karageorgos, M. H. Brown, R. Morona, and P. A. Manning. 1995. A putative pathway for perosamine biosynthesis is the first function encoded within the rfb region of Vibrio cholerae O1. Gene 166:33-42.
74. Sur, D., A. Lopez, S. Kanungo, A. Paisley, B. Manna, M. Ali, S. K. Niyogi, J. K. Park, B. Sarkar, M. K. Puri, D. Kim, J. Deen, J. Holmgren, R. Carbis, R. Rao, T. V. Nguyen, A. Donner, N. K. Ganguly, G. B. Nair, S. Bhattacharya, and J. Clemens. 2009. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 374:1694-1702.
75. Tacket, C. O., M. B. Cohen, S. S. Wasserman, G. Losonsky, S. Livio, K. Kotloff, R. Edelman, J. B. Kaper, S. J. Cryz, R. A. Giannella, G. Schiff, and M. M. Levine. 1999. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect. Immun. 67:6341-6345.
76. Tan, L. K., G. M. Carlone, and R. Borrow. 2010. Advances in the development of vaccines against Neisseria meningitidis. N. Engl. J. Med. 362:1511-1520.
77. Taylor, D. N., K. P. Killeen, D. C. Hack, J. R. Kenner, T. S. Coster, D. T. Beattie, J. Ezzell, T. Hyman, A. Trofa, M. H. Sjogren, et al. 1994. Development of a live, oral, attenuated vaccine against El Tor cholera. J. Infect. Dis. 170:1518-1523.
78. Trach, D. D., J. D. Clemens, N. T. Ke, H. T. Thuy, N. D. Son, D. G. Canh, P. V. Hang, and M. R. Rao. 1997. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349:231-235.
79. van Ginkel, F. W., R. J. Jackson, Y. Yuki, and J. R. McGhee. 2000. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165:4778-4782.
80. Villeneuve, S., A. Boutonnier, L. A. Mulard, and J. M. Fournier. 1999. Immunochemical characterization of an Ogawa-Inaba common antigenic determinant of Vibrio cholerae O1. Microbiology 145:2477-2484.
81. Villeneuve, S., H. Souchon, M. M. Riottot, J. C. Mazie, P. Lei, C. P. Glaudemans, P. Kovác, J. M. Fournier, and P. M. Alzari. 2000. Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity. Proc. Natl. Acad. Sci. U. S. A. 97:8433-8438.
82. Wachsmuth, I. K., G. M. Evins, P. I. Fields, O. Olsvik, T. Popovic, C. A. Bopp, J. G. Wells, C. Carrillo, and P. A. Blake. 1993. The molecular epidemiology of cholera in Latin America. J. Infect. Dis. 167:621-626.
83. Waldor, M. K., R. Colwell, and J. J. Mekalanos. 1994. The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants. Proc. Natl. Acad. Sci. U. S. A. 91:11388-11392.
84. WHO. 2004. Guidelines for the production and control of inactivated oral cholera vaccines. World Health Organization, Geneva, Switzerland.
85. Yildiz, F. H., and G. K. Schoolnik. 1998. Role of rpoS in stress survival and virulence of Vibrio cholerae. J. Bacteriol. 180:773-784.